EZH2 and Miyoshi myopathy: Alzrigat et al. [105] found that treatment of multiple myeloma (MM) patients with a histone methyltransferase enhancer of zeste homolog 2 (EZH2) inhibitor resulted in the reactivation of the expression of hsa-miR-320c, leading to downregulated expression of MM-associated oncogenes.